Yen-I Chen

Yen-I Chen

Auto-generated profile, based on publicly available information

Yen-I Chen

Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2016 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
YCYen-I Chen
Yen-I Chen
Tkao ItoiTkao Itoi
Tkao Itoi
TBTodd H. Baron
Todd H. Baron
JNJose Nieto
Jose Nieto
YHYamile Haito-Chavez
Yamile Haito-Chavez
MKMouen A. Khashab
Mouen A. Khashab

1 June 2018 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
OGOlaya Brewer Gutierrez
Olaya Brewer Gutierrez
NBNoor L.H. Bekkali
Noor L.H. Bekkali
IRIsaac Raijman
Isaac Raijman
RSRichard Sturgess
Richard Sturgess
DSDivyesh V. Sejpal
Divyesh V. Sejpal
MKMouen A. Khashab
Mouen A. Khashab

27 January 2021 in Endoscopy
Verified
Journal Article
Closed access
PDF file
YCYen-I Chen
Yen-I Chen
ACAvijit Chatterjee
Avijit Chatterjee
RBRobert Berger
Robert Berger
YKYonca Kanber
Yonca Kanber
JWJonathan M Wyse
Jonathan M Wyse
CWClarence K Wong
Clarence K Wong
Background Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the standard in the diagnosis of solid pancreatic lesions, in particular when combined with rapid onsite evaluation of cytopathology (ROSE). More recently, a fork-tip needle for core biopsy (FNB) has been shown to be associated with excellent diagnostic yield. EUS-FNB alone has however not been compared with EUS-FNA + ROSE in a large clinical trial. Our aim was to compare EUS-FNB alone to EUS-FNA + ROSE in solid pancreatic lesions.Methods A multicenter, non-inferiority, randomized controlled trial involving seven centers was performed. Solid pancreatic lesions referred for EUS were considered for inclusion. The primary end point was diagnostic accuracy. Secondary end points included sensitivity/specificity, mean number of needle passes, and cost.Results 235 patients were randomized: 115 EUS-FNB alone and 120 EUS-FNA + ROSE. Overall, 217 patients had malignant histology. The diagnostic accuracy for malignancy of EUS-FNB alone was non-inferior to EUS-FNA + ROSE at 92.2 % (95 %CI 86.6 %–96.9 %) and 93.3 % (95 %CI 88.8 %–97.9 %), respectively (P = 0.72). Diagnostic sensitivity for malignancy was 92.5 % (95 %CI 85.7 %–96.7 %) for EUS-FNB alone vs. 96.5 % (93.0 %–98.6 %) for EUS-FNA + ROSE (P = 0.46), while specificity was 100 % in both. Adequate histological yield was obtained in 87.5 % of the EUS-FNB samples. The mean (SD) number of needle passes and procedure time favored EUS-FNB alone (2.3 [0.6] passes vs. 3.0 [1.1] passes [P < 0.001]; and 19.3 [8.0] vs. 22.7 [10.8] minutes [P = 0.008]). EUS-FNB alone cost on average 45 US dollars more than EUS-FNA + ROSE.Conclusion EUS-FNB alone is non-inferior to EUS-FNA + ROSE and is associated with fewer needle passes, shorter procedure time, and excellent histological yield at comparable cost.

14 June 2021 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
MBMateus Bond Boghossian
Mateus Bond Boghossian
MFMateus Pereira Funari
Mateus Pereira Funari
EMEduardo Guimarães Hourneaux de Moura
Eduardo Guimarães Hourneaux de Moura
TMThomas R McCarty
Thomas R McCarty
VSVitor Massaro Takamatsu Sagae
Vitor Massaro Takamatsu Sagae
EMEduardo Guimarães Hourneaux de Moura
Eduardo Guimarães Hourneaux de Moura

1 August 2021 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
Bayview CenterBayview Center
Bayview Center
LFLorenzo Ferri
Lorenzo Ferri
HAHiroyuki Aihara
Hiroyuki Aihara
PDPeter V. Draganov
Peter V. Draganov
DYDennis J. Yang
Dennis J. Yang
AKAntony N. Kalloo
Antony N. Kalloo

22 October 2019 in Endoscopy International Open
Verified
Journal Article
Open access
PDF file
CMCorey S. Miller
Corey S. Miller
ABAlan N. Barkun
Alan N. Barkun
MMMyriam Martel
Myriam Martel
YCYen-I Chen
Yen-I Chen
Background and study aims Endoscopic ultrasound (EUS)-guided biliary drainage (BD) is increasingly used for distal malignant biliary obstruction, yet its safety and efficacy compared to endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic biliary drainage (PTBD) remain unclear. We performed a meta-analysis to improve our understanding of the role of EUS-BD in this patient population. Methods We searched Embase, MEDLINE, CENTRAL, and ISI Web of Knowledge through September 2018 for randomized controlled trials (RCTs) comparing EUS-BD to ERCP-BD or PTBD as treatment of distal malignant biliary obstruction. Risk ratios (RRs) with 95 % confidence intervals (CIs) were combined using random effects models. The primary outcome was risk of stent/catheter dysfunction requiring reintervention. Results Of six trials identified, three (n = 222) compared EUS-BD to ERCP-BD for first-line therapy; three others (n = 132) evaluated EUS-BD versus PTBD after failed ERCP-BD. EUS-BD was associated with a decreased risk of stent/catheter dysfunction overall (RR, 0.39; 95 %CI 0.27 – 0.57) and in planned subgroup analysis when compared to ERCP (RR, 0.41; 95 %CI 0.23 – 0.74) or PTBD (RR, 0.37, 95 %CI 0.22 – 0.61). Compared to ERCP, EUS was associated with a decreased risk of post-procedure pancreatitis (RR, 0.12; 95 %CI 0.01 – 0.97). No differences were noted in technical or clinical success. Conclusions In a meta-analysis of randomized trials comparing EUS-BD to conventional biliary drainage modalities, no difference in technical or clinical success was observed. Importantly, EUS-BD was associated with decreased risks of stent/catheter dysfunction when compared to both PTBD and ERCP, and decreased post-procedure pancreatitis when compared to ERCP, suggesting the potential role for EUS-BD as an alternative first-line therapy in distal malignant biliary obstruction.